Valuation Actinium Pharmaceuticals, Inc. Deutsche Boerse AG
Stocks
7AY1
US00507W2061
Biotechnology & Medical Research
|
Market Closed -
Deutsche Boerse AG
09:00:08 01/10/2026 +03
|
After hours 23:00:01 | |||
| 0.9690 EUR | -1.52% |
|
1.015 | +4.75% |
| 08-15 | Actinium Pharmaceuticals Expands Manufacturing Capacity for Actimab-A Program | CI |
| 08-15 | Actinium Pharmaceuticals, Inc. Amends Its Investigational New Drug | CI |
Company Valuation: Actinium Pharmaceuticals, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 132.4 | 271.4 | 139.3 | 39.31 | 42.43 | 35.21 | - | - |
| Change | - | 104.97% | -48.69% | -71.77% | 7.94% | -17% | - | - |
| Enterprise Value (EV) | 132.4 | 271.4 | 62.58 | 39.31 | 42.43 | 35.21 | 35.21 | 35.21 |
| Change | - | 104.97% | -76.94% | -37.19% | 7.94% | -17% | 0% | 0% |
| P/E | -5.01x | -7.77x | -2.78x | -0.99x | -1.25x | 6.51x | -1.72x | -2.97x |
| PBR | 1.81x | - | 3.72x | - | - | - | - | - |
| PEG | - | -0.5x | -0.1x | 0x | 0.1x | -0x | 0x | 0.1x |
| Capitalization / Revenue | 116x | 263x | 1,719x | - | 471x | 2.01x | - | 2.02x |
| EV / Revenue | 0x | 0x | 0x | - | 0x | 2.01x | - | 2.02x |
| EV / EBITDA | -0x | -0x | -0x | -0x | -0x | 14.7x | -0.95x | -0.86x |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | 6.77x | -1.06x | -1.57x |
| EV / FCF | -0x | 0x | -0x | -0x | - | 1.63x | -1.3x | -1.45x |
| FCF Yield | -15.9% | 3.05% | -34.1% | -84.2% | - | 61.4% | -76.7% | -69% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -1.2 | -1.37 | -1.83 | -1.27 | -1.09 | 0.1767 | -0.67 | -0.3875 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 1.144 | 1.03 | 0.081 | - | 0.09 | 17.5 | - | 17.46 |
| EBITDA 1 | -24.44 | -33.4 | -51.13 | -41.31 | -35.43 | 2.4 | -37.1 | -41.1 |
| EBIT 1 | -24.96 | -34.1 | -51.92 | -42.12 | -36.25 | 5.201 | -33.35 | -22.45 |
| Net income 1 | -24.77 | -33.02 | -48.82 | -38.24 | -33.89 | 5.912 | -30.95 | -19.95 |
| Net Debt | - | - | -76.68 | - | - | - | - | - |
| Reference price 2 | 6.010 | 10.650 | 5.080 | 1.260 | 1.360 | 1.150 | 1.150 | 1.150 |
| Nbr of stocks (in thousands) | 22,031 | 25,483 | 27,413 | 31,196 | 31,196 | 31,441 | - | - |
| Announcement Date | 3/25/22 A | 3/31/23 A | 3/29/24 A | 3/31/25 A | 3/30/26 A | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 21.73x | 7.77x | 15.61x | 1.37% | 74.46B | |
| 31.25x | 9.01x | 28.06x | 0.04% | 60.14B | |
| 33.64x | 6.03x | 18.07x | 0.97% | 48.15B | |
| 34.63x | 3.34x | 14.4x | -.--% | 44.25B | |
| -21.16x | 229.18x | -22.81x | -.--% | 43.99B | |
| 47.94x | 5.54x | 30.43x | -.--% | 41.61B | |
| 26.89x | 7.76x | 19.96x | 0.42% | 29.97B | |
| 33.91x | 7.26x | 18.84x | -.--% | 29.31B | |
| -70.02x | 13.44x | -68.51x | -.--% | 24.93B | |
| Average | 15.42x | 32.15x | 6.01x | 0.31% | 44.09B | |
| Weighted average by Cap. | 19.58x | 31.88x | 10.24x | 0.41% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- ATNM Stock
- 7AY1 Stock
- Valuation Actinium Pharmaceuticals, Inc.
Select your edition
All financial news and data tailored to specific country editions
